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Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid
and Plasma Cell Neoplasm
Shanxiang Zhang, MD, PhD* and Catherine Long, MDw
Summary: Pediatric neoplasm with monoclonal proliferation of
lymphoplasmacytoid lymphocytes and plasma cells is exceedingly
rare and has essentially never been reported in immunocompetent
children. Here, we report a previously healthy 13-year-old girl with a
pharyngeal mass and enlarged cervical lymph nodes. The pharyngeal
mass was composed of CD138+, CD79a+, MUM-1+, IgD+,
CD20, PAX-5, CD43, l-restricted monoclonal plasmacytoid,
and plasma cells. Scattered CD20+, PAX-5+ B cells were present in
the background. The patient was treated as localized non-Hodgkin
lymphoma (stage II) with cyclophosphamide, doxorubicin, vincris-
tine, and prednisone and is in complete remission at 17 months from
the last chemotherapy.
Key Words: immunocompetent children, neoplasm, lympho-
plasmacytoid lymphocytes, plasma cells, immunoglobulin D
positiveAQ2
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Pediatric non-Hodgkin B-cell lymphoma mainly includesBurkitt lymphoma and diﬀuse large B-cell lymphoma.1
Indolent B-cell lymphoma in children is uncommon and is
mainly comprised of marginal zone lymphoma (MZL) and
follicular lymphoma.2,3 Pediatric MZL, unlike MZL in the
adult population, predominantly includes nodal MZL.4,5
Extranodal MZL in children has rarely been reported and
involved sites include the gastrointestinal tract, skin, orbits,
salivary glands, tonsils, adenoids, appendix, lung, breast, and
thymus.4–9 Other types of pediatric non-Hodgkin B-cell
lymphoma, such as lymphoplasmacytic lymphoma (LPL)
and plasma cell neoplasm (PCN), are exceedingly rare.6,10–12
Here, we report a neoplasm composed of predominantly
immunoglobulin (Ig)D-positive monoclonal plasmacytoid
and plasma cells in an immunocompetent 13-year-old girl
with pharyngeal mass and cervical lymphadenopathy.
CASE REPORT
A 13-year-old girl with a history of tonsillectomy at age 3
noticed an abnormal mass in her throat with occasional pain.
Physical examination revealed a submucosal linear mass measuring
41 cm, located in right posterior oropharynx near the old tonsil
fossa. An ENT physician at an outside institution performed an
excisional biopsy of the mass. Upon pathology report from that
institution she was referred to our tertiary care center [Indiana
University Health (IUH)] for further evaluation. She had no fever,
night sweats, or weight loss. Her past medical history was otherwise
unremarkable. Her family medical history included cervical cancer
in her maternal grandmother, thyroid cancers in the sister and niece
of her maternal grandmother, and lymphoma (type unknown) in
her paternal grandfather. There was no family history of immu-
nodeﬁciency. A whole body computed tomography and positron-
emission tomography scan revealed enlarged, bilateral, hyper-
metabolic, level II cervical lymph nodes, abnormal fullness, and
intense metabolic activity in the lymphoid tissue in the tongue base,
oropharynx, and nasopharynx. There was no evidence of meta-
static disease outside of the neck. Her blood analysis showed
normal complete blood count (white blood cells: 7.0 k/mm3, ref-
erence: 4.5 to 11.5 k/mm3; hemoglobin: 13.4 g/dL, reference: 12 to
15 g/dL; platelet: 195 k/mm3, reference: 150 to 450 k/mm3) and
diﬀerential (56% neutrophils, 33% lymphocytes, and 9% mono-
cytes), normal liver/renal functions, normal lactate dehydrogenase
(162U/L, reference: 100 to 242U/L), and normal uric acid (5.4mg/
dL, reference: 2 to 7mg/dL).
Review of the excisional biopsy at IUH revealed histologi-
cally unremarkable squamous mucosa overlying marked pro-
liferation of predominantly plasmacytoid lymphocytes and plasma
cells. There were few scattered and rare aggregates of small lym-
phocytes (Fig. 1A). Few residual salivary glands and rare follicles
with germinal centers were noted. Immunohistochemical stains
(Figs. 1B–H) performed at IUH showed the great majority of cells
to be positive for CD79a, CD138, VS38, MUM-1, IgD, l light
chain, and negative for CD3, CD20, PAX-5, CD5, CD10, CD23,
CD43, cyclin D1, SOX11, BCL-6, CD56, CD117, CD123, k light
chain, IgG, IgA, IgM, and S-100. The proliferative index as
revealed by Ki-67 stain was low (<10%). There were few CD20+
and/or PAX-5+ B cells in the background. CD21 and CD23 stains
revealed rare follicular dendritic cell meshworks. Viral stain for
HHV8 and in situ hybridization for Epstein-Barr virus-encoded
RNAs (EBER) were negative. Per pathology report from Amer-
iPath Indiana (Indianapolis, Indiana), ﬂow cytometric analysis
(FCA) revealed a low-viability (approximately 25%) sample with
few polyclonal B cells and immunophenotypically unremarkable T
cells (markers tested: CD3, CD4, CD5, CD7, CD8, CD10, CD19,
CD20, CD23, CD38, CD45, CD56, FMC7, sKappa, and
sLambda). No FCA for plasma cells was performed. Fluorescence
in situ hybridization performed at IUH revealed no API/MALT1
fusion or copy number changes of AP1 and MALT1 genes.
Molecular study with multiplex PCR AQ3performed at IUH showed
clonal Ig heavy chain g rearrangement (Fig. 2). No cytogenetic/
karyotyping study was performed at either outside or our own
institute. A descriptive diagnosis of monoclonal plasmacytoid and
PCN, most compatible with extranodal MZL of mucosa-associated
lymphoid tissue (MALT lymphoma) with plasmacytic diﬀer-
entiation was rendered. Subsequent bilateral bone marrow exami-
nations performed at IUH revealed few scattered l-predominant
plasmacytoid/plasma cells (supplemental Fig. 1, Supplemental
Digital Content 1, http://links.lww.com/JPHO/A91, http://links.lww.
com/JPHO/A92, http://links.lww.com/JPHO/A93, http://links.
lww.com/JPHO/A94, http://links.lww.com/JPHO/A95). Molecular
study of the bone marrow aspirate with multiplex PCR performed at
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IUH revealed no clonal Ig heavy chain g rearrangement (data not
shown).
As pediatric MALT lymphoma has been reported in immu-
nodeﬁcient patients and gastric MALT lymphoma is associated
with Helicobacter pylori (H. pylori) infection, the patient was
evaluated for T-cell and B-cell subsets, Ig levels including IgG with
subclasses IgA, IgM, and IgE, HIV, hepatitis panel, and H. pylori
infection. There was a borderline increase in her serum IgG anti-
body (1.03, reference range: <0.75) against H. pylori. The patient
had normal serum levels of IgA (112mg/dL, reference: 47 to
317mg/dL), IgM (72mg/dL, reference: 56 to 242mg/dL), IgE
(14 kU/L, reference: 2 to 114 kU/L), and IgG (838mg/dL, refer-
ence: 680 to 1531mg/dL) including its subclasses. B-cell (355/mm3,
reference 200 to 1259/mm3) and T-cell (1524/mm3, reference: 1072
to 3890/mm3) counts and their subsets were within normal refer-
ence range. Serum studies for hepatitis A, B, C, and HIV were all
negative. There was no monoclonal protein by serum protein
electrophoresis test.
The patient was treated as stage II non-Hodgkin lymphoma
(NHL) per POG9219 protocol (https://members.childrensoncology
group.org/prot/ProtInfo.asp?ProtocolNum=9219&Disease=NHL).
A 6-week induction phase included vincristine 1.5mg/m2 weekly for 6
doses, doxorubicin 40mg/m2 and cyclophosphamide 750mg/m2 on
days 1 and 22, respectively, and prednisone 40mg/m2/d for 28 days.
This was followed by a shorter consolidation phase consisting of a
single dose each of vincristine 1.5mg/m2, doxorubicin 40mg/m2, and
cyclophosphamide 750mg/m2 along with 5 days of prednisone
40mg/m2/d. She was also treated with lansoprazole, amoxicillin, and
clarithromycin for H. pylori due to positive H. pylori IgG antibody.
Her postchemotherapy computed tomography and positron-emission
tomography scan performed 1 week after completing chemotherapy
revealed resolution of previous disease. Since that time she has been
followed clinically and is currently in complete remission at 17
months from her last chemotherapy.
DISCUSSION
Small B-cell lymphoma with plasmacytic diﬀer-
entiation is used to describe a neoplasm of small B cells,
plasmacytoid lymphocytes, and plasma cells. The major
diﬀerential diagnosis includes MZL with plasmacytic dif-
ferentiation and LPL.13 In the pediatric population, MZL
has been rarely reported including MZL with plasmacytic
diﬀerentiation. However, essentially all the reported MZL
cases contained aggregates and sheets of CD20+ B cells.3,5
Pediatric MZL tends to be IgD-negative and presents with
localized disease (stage I).5 The lesion in our case involved
the patient’s oropharynx and cervical lymph nodes (stage
II). Histologically, the lesion was composed of sheets of
IgD-positive, l-restricted monoclonal plasmacytoid lym-
phocytes and/or plasma cells. There were rare follicles as
indicated by CD21 and CD23 stains. CD20 and PAX-5
stains revealed few B cells. The B cells were shown to be
polyclonal by FCA, although the viability of the sample
was very low (approximately 25%). The few B cells in our
case were CD43, although the B cells in the reported
pediatric MZL tend to be CD43+. There were no back-
ground progressive transformed germinal centers as
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FIGURE 1. Morphologic and immunophenotypical features of pharyngeal mass. A, Hematoxylin and eosin, magnification: 200. B–H,
Immunohistochemistry, magnification: 200. B, CD20; C, CD138: D, CD79a; E, kappa; F, lambda; G, IgD; H, Ki-67.
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reported in pediatric nodal MZL; or monocytoid B cells
and lymphoepithelial lesions as commonly seen in extra-
nodal MZL.5 The molecular test (PCR) demonstrated
clonal Ig heavy chain g gene rearrangements, which sup-
ported a clonal neoplastic process. Overall we favor this
lesion to be a B-cell lymphoma with extreme plasmacytic
diﬀerentiation, although the presence of few CD43 B cells
added the diﬃculty of recognizing this case as a B-cell
neoplasm.
LPL is essentially an adult disease.13 To our knowl-
edge there were only 2 reported pediatric cases of LPL/
LPL-like lesions which were both associated with Wiskott-
Aldrich syndrome and were self-limited.12,14 Our patient
did not have any history of recurrent infections and workup
for possible immunodeﬁciency was negative. Similarly,
PCN is exceedingly rare in children and is by current World
Health Organization deﬁnition a neoplasm secreting heavy
chain class-switched Ig.15 Morphologically, however, our
case was most compatible with LPL or PCN. As pediatric
LPL and PCN are either extremely rare or have not been
widely accepted in literature, and LPL in adults is typically
IgD-negative, we were hesitant to render a diagnosis of
LPL or PCN for this lesion.
Plasmablastic lymphoma (PBL) is a diﬀuse proliferation
of large neoplastic cells which morphologically resemble B
immunoblasts, but with the immunophenotype of plasma
cells. The tumor cells are positive for CD138, CD38, VS38c,
MUM-1, CD79 (majority), and are negative or only weakly
positive for CD45, CD20, and PAX-5. The Epstein-Barr
virus study (EBER) is commonly positive. PBL is an
aggressive lymphoma typically with a high proliferation
fraction. Patients with PBL usually have advanced disease
(stage III or IV) and die within the ﬁrst year after diagnosis.16
Although it is most commonly seen in HIV-positive
individuals, PBL has been reported in immunocompetent
individuals. However, almost all PBL reported in immuno-
competent individuals is seen in adults, whereas pediatric
PBL is reported only in HIV-positive children.17–19 Our
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FIGURE 2. Monoclonal gene arrangement of the immunoglo-
bulin heavy chain gamma by PCR using InVivoScribe (San Diego,
CA) kit. A, Primer set FR1-JH, 339 base pairs (bp). B, Primer set
FR2-JH, 275bp.
TABLE 1. Comparison of Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, and Plasmablastic Lymphoma in Pediatric
Population
Marginal Zone Lymphoma
Nodal Extranodal
Lymphoplasmacytic
Lymphoma Plasmablastic Lymphoma
Common aﬀected
sites
Head and neck LN, lymphoid
tissue
Ocular adnexa, salivary
glands, skin
Generalized
lymphadenopathy
Head and neck, skin
Pathologic
description
Small to intermediate
lymphocytes with scattered
plasma cells, marginal zone
expansion, PTGC features
Monocytoid cells,
plasma cells,
lymphoepithelial
lesions, architectural
distortion
Numerous plasma cells
with scattered small
lymphocytes
Large plasmablastic cells with
conspicuous nucleoli and
basophilic cytoplasm, sheet-
like or nest-like growth pattern
Immunophenotype CD20+, CD43+
(B70%), CD5,
CD10, BCL-6
CD138+ and IgG+
plasma cells and
CD20+, CD5,
CD10, CD43 B
cells
CD45+/CD45, CD20,
VS38c+ , MUM-1+,
CD79a/CD79a+, EMA+,
EBER+, CD56, Ki-67
high (>75%)
Associated
features
Predominantly male; stage I,
rarely II, III
Few with autoimmune
disease; Helicobacter
pylori in gastric MZL;
stage I, rarely II, III
Wiskott-Aldrich
syndrome and 1 case
also with Von
Recklinghausen
neuroﬁbromatosis
More males; predominantly
HIV+; stage III and IV,
rarely II
Molecular markers Few trisomies 18, 3 Rare trisomy 3, IGH-
MALT1, tetraploidy
Unknown Possible t(8;14), IGH/MYC
Treatment Excision, CT, RT RT, CT, excision None HAART, HARRT+CT, with
or without RT
Outcome/survival Excellent Excellent Self-limited Dismal, most died within 1.5 y
CT indicates chemotherapy; EBER, Epstein-Barr virus-encoded RNAs; EMA, epithelial membrane antigen; HARRT, highly active antiretroviral therapy;
MZL, marginal zone lymphoma; PTGC, progressive transformation of germinal centers; RT, radiation therapy.
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patient was a previously healthy teenager who presented with
a localized disease (stage II). The neoplasm she had showed
very low proliferation index (<10%) as indicated by Ki-67
stain. The patient has been disease free for 17 months after
receiving treatment for low-grade B-cell lymphoma. The
initial clinicopathologic presentation as well as the disease
response to the treatment makes the diagnosis of PBL highly
unlikely. The major clinicopathologic features including
treatment and prognosis for pediatric MZL, LPL, and PBL
were summarized in Table 1. Other diﬀerential diagnosis
includes atypical marginal zone hyperplasia with l light chain
restriction. These cases reported by Attygalle and colleagues
all showed CD20+ B cells in the expanded marginal zone
and follicular hyperplasia. These B cells were IgM, IgD-
positive, and showed high proliferation index by Ki-67 stain.
There was no signiﬁcant plasmacytic diﬀerentiation in the
reported 6 cases. No evidence of clonality at the genetic level
was demonstrated by PCR analysis.20 Our case instead
showed predominantly IgD-positive, IgM-negative plasma-
cytoid, and plasma cells with both l chain restriction by
immunohistochemical stains and clonality by PCR analysis.
Here, we reported a highly unusual case of clinically
stage II neoplasm composed of predominantly IgD-positive,
l-restricted monoclonal plasmacytoid, and plasma cells,
morphologically most compatible with LPL or PCN, in a 13-
year-old girl with no signiﬁcant past medical history. The
patient was treated per POG9219 protocol for localized NHL
and remains in complete remission 17 months after her last
chemotherapy. In patients with localized (stage I or II) NHL
treated with POG9219, the 5-year event-free survival is
83.7%, with an overall survival of 96%. The standard follow-
up includes complete blood count along with clinical history
and physical examination. No imaging is necessary unless a
relapse was suspected if the patient was in full remission at
the end of therapy (https://members.childrensoncologygroup.
org/prot/ProtInfo.asp?ProtocolNum=9219&Disease=NHL).
Could this case represent an authentic pediatric LPL or PCN,
or just a MZL with extreme plasmacytic diﬀerentiation? In
adults, the distinction between B-cell lymphoma with plas-
macytic diﬀerentiation and PCN is critical as they require
diﬀerent treatment. In the pediatric population, MZL usually
requires only local treatment with long-term follow-up.5 For
our patient, long-term clinical follow-up may be helpful in the
diﬀerential diagnosis. Report of other similar cases may also
help to answer this question.
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